Video

Medicolegal 101 for the Urologist: Lawsuits and Expert Witnesses

William O. Brant, MD, FACS, FECSM, a urologist at the Veterans Affairs Medical Center in Salt Lake City, Utah, discusses medical lawsuits from the perspective of a physician being sued or suggested preparation to be an expert witness. 

He describes the four elements of malpractice patients need to prove when filing a summons or other “pleadings,” which are: A professional duty is owed to a patient, that duty has been breached, this breach caused an injury, and damages (either monetary or punitive) resulted from that injury. To prove negligence, the conduct of a physician is judged against a standard, defined as care that a “reasonable,” similarly-situated urologist would have provided. From there, the process of discovery ensues. Then, the case may or may not proceed to trial, although due to the United States’ “adversarial” system, it is rare this happens. In terms of lawyers playing a role in medicolegal cases, it is important to note that plaintiffs typically work on contingency and take cases with high monetary damages and likely appeal to juries, while defendants are typically appointed by a medical malpractice company. 

For the urologist cautious about patients suing, Dr. Brant points to a descriptive series review that reported that the leading reason for choosing to litigate is a perceived poor relationship with the provider. In his data, patients who sue often have a poor relationship with their provider or medical malpractice was suggested by another provider. In an AUA survey, while 63% of participants were named in a suit, 47% dropped without financial settlement.

Despite the low patient success rate of 4%, lawsuits can affect urologists. In the study 60% of participants considered limiting their scope of practice with ramifications of 27%-39% experiencing symptoms of major depressive disorder. Brant highlights that lawsuits can feel like a personal assault or failure, but they are truly about compensation.

In his personal experience as an expert witness, Brant has been involved in about 100 cases over 20 years. Qualifications include specialized education and practical experience, but vary by state. The AUA Expert Witness Affirmation Statement, signed as part of AUA membership, supports testifying within your field, distinguishing between bad outcome and bad practice, and being willing to testify for plaintiff or defendant as “you’re not on anyone’s side.”

When looking for an expert witness, Brant thinks lawyers are looking for consistent, strong, credible testimony. Lawyers ask a lot of “why” questions to learn an expert’s theory and factual basis, in addition to how they would handle cross-examination. When acting as an expert witness, Brant recommends: Don’t elaborate or volunteer information. Methods that can be used against the expert witness include trying to blame a provider, multi-part or repeated questions, and agreeing to generalizations or “standard” texts. Brant also suggests avoiding answering a question you don’t understand. An expert witness can ask questions or clarify, and he reminds any potential witnesses it is okay not to have the answer. He also recommends avoiding absolutes and adopting the language of a question if it is misleading or inappropriate.

Read More

Review of the New Standard in Treatment and Global Issues: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis Inhibitors

Marc B. Garnick, MD, Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, reviews current literature on the treatment of prostate cancer. Dr. Garnick focuses specifically on Androgen Deprivation Therapy (ADT,) Chemotherapy, Androgen Receptor Inhibitors, and Androgen Synthesis Inhibitors.

In this presentation, Dr. Garnick explores the current landscape of Advanced Prostate Cancer Treatments, the use of triplet therapies in combating metastatic Castration-Sensitive Prostate Cancer (mCSPC), and the possibility of avoiding ADT by combining advanced imaging techniques with Metastases-Directed Therapy (MDT).

Read More

NMIBC Trials for BCG Naive Patients: What is Exciting

Joshua J. Meeks, MD, PhD, Associate Professor of Urology, Biochemistry and Molecular Genetics at the Northwestern University Feinberg School of Medicine in Chicago, IL, provides insights into the latest advancements in bladder cancer research. He highlights the potential of large-scale clinical trials and the role of immunotherapy in shaping future treatment strategies. The North American trial, with a thousand patients, offers numerous opportunities to explore new treatment modalities. Additionally, the Bridge study led by Max Kate examines the efficacy of gemcitabine docetaxel compared to the standard BCG treatment. Despite initial skepticism, the trial presents promising results that may offer an alternative for patients who cannot access BCG. Dr. Meeks emphasizes the importance of identifying the patient population that would benefit most from checkpoint immunotherapy and coordinating care effectively.

He discusses ongoing trials that investigate the synergy between immunotherapy and BCG, the possibility of using less BCG, and the introduction of a Sub-Q delivery system. The Sunrise trials, TAR 200, and the Danish study DaBlaCa all hold potential in improving treatment outcomes for bladder cancer patients. Dr. Meeks concludes by highlighting the transformative impact of the Terra system, a device that delivers gemcitabine consistently and may revolutionize bladder cancer treatment. Overall, this comprehensive summary underscores the significant advancements and future prospects in bladder cancer research.

Read More

The Impact of The Debt Ceiling and Rising Healthcare Costs on Physicians

Congressman Gregory F. Murphy, MD, a practicing urologist and the Representative from North Carolina’s 3rd District, speaks with E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, about the impact of the National Debt and rising healthcare costs on physicians and individual practices.

In this 11-minute conversation, they discuss, the reason why practices are often targeted for healthcare cuts, the role of healthcare “middlemen” and insurance companies in the rise of healthcare costs, and the impact of the Debt Ceiling on healthcare practices.

Read More

Caring for Underserved and Vulnerable Populations for Over 23 Years

Fernando Kim, MD, MBA, FACS, Chief Emeritus of Urology at Denver Health Medical Center and Professor of Surgery/Urology at the University of Colorado at Denver, shares insights gathered from his more than 23 years of caring for underserved and vulnerable populations. Dr. Kim describes some of the needs and characteristics of these populations, and gives examples of the traumatic experiences to which those populations are regularly exposed. He also emphasizes the importance of physicians understanding their patients’ cultures, communication styles, and needs so that they can effectively treat those patients.

He addresses time constraints for patients who cannot afford to be out of work, and how developing a minimally-invasive practice can help support those patients. He cites disparate oncological profiles along demographic lines, as well as research that supports multiple factors influencing patient treatment selection. For example, he explains that, especially for African-American men, the less invasive nature of cryoablation appeared to influence opinions regarding surgery for the treatment of localized prostate cancer.

Dr. Kim cites another study that reaffirms the importance in health disparities research of modeling interactions between race/ethnicity and variables that reflect diverse aspects of a patient’s socioeconomic circumstances, since the research showed that doctors’ treatment recommendations were less aggressive for poor or indigent populations. He concludes by reemphasizing the importance of empathy, cultural humility, and understanding when working with vulnerable and underserved communities.

Read More